EXPEDITORS INTERNATIONAL OF WASHINGTON INC
No SEC Form 4 filings for $EXPD in the last 30 days.
Expedition raised $115m in a Series B to advance its COPD drug EXPD-101 through an ongoing Phase II trial (NCT07684820), and to expand its pipeline and discovery platform, according to CEO Yi Larson. EXPD-101 targets neutrophilic inflammation via DPP1 inhibition. The company cited prior Phase I results showing tolerability and once-daily oral dosing support.
Analyst actions highlighted: Argus upgraded Bristol Myers (BMY) to Buy, $75 target, citing margin improvement and raised 2026 guidance. Freedom Broker upgraded McDonald's (MCD) to Buy, $305 target, on softer revenue and comps. Morgan Stanley upgraded Humana (HUM) to Equal Weight, $370 target. Jefferies downgraded Best Buy (BBY) to Hold, $85 target. Others included upgrades/downgrades for several stocks with updated price targets.
The NYSE pre-market update says the Dow rose above 54,000 for the first time and the S&P 500 closed above 7,700. It notes Expedition Therapeutics secured a $115 million Series B and that first patients were dosed in its Phase 2 trial for EXPD-101 in COPD. It also references Zeta Global’s Q2 beat-and-raise results.
Over the past 7 days, alphai's AI scored 8 news stories mentioning EXPD (EXPEDITORS INTERNATIONAL OF WASHINGTON INC). Coverage has skewed bullish: 6 bullish, 2 neutral, and 0 bearish.
Recent EXPD coverage spans earnings, financial news and corporate actions.
The financing reduces near-term funding risk for EXPD-101’s Phase II execution, supporting a longer runway into upcoming clinical/regulatory milestones.
Neutral rating with a higher target implies stabilization, but not a strong conviction buy.
The disclosed Series B size and Phase 2 dosing milestone are incremental funding and clinical-readout signals that can shift near-term risk appetite for the stock.
Strong Q2 earnings beat with broad revenue growth, plus a disclosed $25M pretax restructuring charge and an expected ~$50M annual cost reduction.
Strong Q2 results driven by airfreight capacity tightness and higher late-quarter pricing, plus tariff-related customs activity.
alphai scores every news story that mentions EXPD with an AI model for sentiment and relevance, and aggregates insider trades from EXPEDITORS INTERNATIONAL OF WASHINGTON INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Expedition raised $115m in a Series B to advance its COPD drug EXPD-101 through an ongoing Phase II trial (NCT07684820), and to expand its pipeline and discovery platform, according to CEO Yi Larson. EXPD-101 targets neutrophilic inflammation via DPP1 inhibition. The company cited prior Phase I results showing tolerability and once-daily oral dosing support.
4 min readAnalyst actions highlighted: Argus upgraded Bristol Myers (BMY) to Buy, $75 target, citing margin improvement and raised 2026 guidance. Freedom Broker upgraded McDonald's (MCD) to Buy, $305 target, on softer revenue and comps. Morgan Stanley upgraded Humana (HUM) to Equal Weight, $370 target. Jefferies downgraded Best Buy (BBY) to Hold, $85 target. Others included upgrades/downgrades for several stocks with updated price targets.
7 min readThe NYSE pre-market update says the Dow rose above 54,000 for the first time and the S&P 500 closed above 7,700. It notes Expedition Therapeutics secured a $115 million Series B and that first patients were dosed in its Phase 2 trial for EXPD-101 in COPD. It also references Zeta Global’s Q2 beat-and-raise results.
2 min readEXPEDITORS INTERNATIONAL OF WASHINGTON INC (EXPD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 expd-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 EARNINGS RELEASE By: Expeditors International of Washington, Inc. 3545 Factoria Blvd. SE Sterling Plaza 2, 3rd Floor Bellevue, Washington 98006 CONTACTS : Daniel R. Wall David A. Hackett Geoffrey Buscher President and Chief E
4 min readExpeditors International reported Q2 results with airfreight volume up 14% year over year (13% April, 14% May, 15% June). Ocean freight was mixed, flat overall. Revenue rose 32% to $3.5B, operating income up 41% to $349.6M, and net income to $2.03 per share. CEO Daniel Wall cited strong air demand and tariff-driven customs activity.
4 min readExpeditors International of Washington (EXPD) reported Q2 earnings of $266.2 million, or $2.03 per share, up from $183.6 million, or $1.34 per share, a year earlier. Revenue increased 32% to $3.502 billion from $2.651 billion. The company said results reflected double-digit growth across most products. EXPD last traded at $171.89 on the NYSE.
2 min readExpeditors (NYSE:EXPD) reported Q2 CY2026 revenue of $3.50 billion, up 32.1% year on year and 18.6% above Wall Street estimates, and GAAP EPS of $2.03, 19.9% above consensus. The board declared a semi-annual dividend of $0.81 per share payable June 15, 2026. Analysts expect revenue growth of 1.1% over the next 12 months.
6 min readExpeditors (NYSE: EXPD) is set to report Q2 results Tuesday before the bell. The article notes last quarter’s revenue was $2.78B, up 4.4% YoY, and it beat analysts on EPS. For this quarter, analysts expect revenue growth of 11.4% YoY. It cites an average price target of $157.14 versus a $166.75 share price.
4 min readOn July 20, 2026, Anduril and Archer Aviation (NYSE: ACHR) unveiled at Farnborough a dual-use autonomous VTOL platform, with a defense variant called Thunder, per Business Wire. Expeditors International (NYSE: EXPD) expanded its Aircraft on Ground coverage. StandardAero (NYSE: SARO) signed an LEAP-1B MRO deal with Arajet. Loganair signed a term sheet to buy BETA Technologies (NYSE: BETA) electric ALIA aircraft.
6 min readExpeditors International (EXPD) is set to report Q2 2026 earnings on Aug. 4 before the open. Analysts expect diluted EPS of $1.64, up from $1.34 a year earlier. For fiscal 2026, EPS is projected at $6.71. The stock has risen 60.5% over 52 weeks; its average price target is $162.
3 min read
